Kimelman & Baird’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kimelman & Baird’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$8.93M	Buy	+65,956	New	+$8.67M	0.8%	37
2019 Q3	$9.11M	Sell	119,498 -820	-0.7%	-$68.1K	1.26%	30
2019 Q2	$10.6M	Sell	120,318 -130	-0.1%	-$11.1K	1.47%	26
2019 Q1	$10.9M	Sell	120,448 -19,100	-14%	-$1.62M	1.57%	26
2018 Q4	$10M	Sell	139,548 -13,518	-9%	-$1.09M	1.56%	27
2018 Q3	$14.7M	Buy	153,066 +176	+0.1%	+$17.1K	1.85%	24
2018 Q2	$14.6M	Buy	+152,890	New	+$14.1M	1.91%	21
2017 Q4	$13M	Buy	153,015 +320	+0.2%	+$26.8K	1.85%	19
2017 Q3	$13.2M	Buy	152,695 +80,055	+110%	+$6.42M	1.97%	20
2017 Q2	$5.61M	Buy	+72,640	New	+$5.15M	0.85%	39

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Kimelman & Baird's XBI Position: Q2 2021 in Review

Kimelman & Baird opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2021: 65,956 shares worth $8.93M. The stake represents 0.8% of the portfolio and ranks #37 among its holdings. This is a return to the name: Kimelman & Baird previously reported a position in XBI as recently as Q3 2019.

Kimelman & Baird first reported a position in XBI in Q2 2017 and has held it in 10 quarters since. The position peaked at $14.7M in Q3 2018. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

Kimelman & Baird held 65,956 shares of State Street SPDR S&P Biotech ETF worth $8.93M as of Q2 2021.
State Street SPDR S&P Biotech ETF was a new Kimelman & Baird position in Q2 2021.
State Street SPDR S&P Biotech ETF made up 0.8% of Kimelman & Baird's portfolio in Q2 2021, its #37 holding.
Kimelman & Baird first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 10 quarters since.
Kimelman & Baird's State Street SPDR S&P Biotech ETF position peaked at $14.7M in Q3 2018.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on Kimelman & Baird's 13F filing for Q2 2021, filed 17 Aug 2021.